# Case Report: Deletion in the 5' untranslated region of TAFAZZIN in a boy with Barth syndrome

**Authors:** Emma S. Singer, Janine Smith, Richard Lin, Ansley M. Morrish, Sean Lal, Claire Irving, Charlene Casey, Ingrid King, Robert G. Weintraub, Richard D. Bagnall

PMC · DOI: 10.3389/fcvm.2026.1766067 · Frontiers in Cardiovascular Medicine · 2026-02-16

## TL;DR

A boy with Barth syndrome had a previously undetected deletion in the TAFAZZIN gene's 5' untranslated region, showing the need to analyze non-coding regions in genetic testing.

## Contribution

A novel 116 bp deletion in the TAFAZZIN gene's 5' untranslated region was identified, preventing protein expression in a Barth syndrome patient.

## Key findings

- A hemizygous 116 base pair deletion in the 5' untranslated region and start codon of TAFAZZIN was identified.
- RNA analysis showed truncated TAFAZZIN transcripts, and Western blotting confirmed loss of full-length protein.
- Phenotype-guided reanalysis of exome data was crucial for identifying the deletion missed by initial testing.

## Abstract

Barth syndrome is an X-linked disorder characterised by cardiomyopathy, growth abnormalities, neutropenia, and 3-methylglutaconic aciduria. It is caused by pathogenic variants in TAFAZZIN, which encodes a mitochondrial protein essential for cardiolipin remodelling. In this study, we describe the case of a patient with Barth syndrome in whom initial research genetic testing missed a 5' untranslated region deletion in TAFAZZIN that was later identified through a phenotype-guided reanalysis of exome sequencing data.

A male infant presented with dilated cardiomyopathy at 7 months of age and underwent cardiac transplantation at 19 months. Initial comprehensive cardiac genetic testing was indeterminate. Subsequent clinical investigations recorded a slight increase in the levels of 3-methylglutaconic acid and intermittent neutropenia, and a history of intermittent neutropenia was noted in his mother and maternal grandmother, prompting a consideration of Barth syndrome. A reanalysis of exome sequencing data identified a hemizygous 116 base pair deletion spanning the 5' untranslated region and start codon of TAFAZZIN. An RNA analysis from the proband's cardiac tissue amplified truncated TAFAZZIN transcripts, and Western blotting confirmed the complete loss of full-length protein, consistent with the loss of the start codon and failure of translation initiation from a downstream in-frame methionine.

We report a novel 116 bp TAFAZZIN deletion that prevents protein expression due to the loss of the canonical start codon. This case highlights the importance of including non-coding regions in genetic analysis and the diagnostic value of phenotype-guided reanalysis of genetic test data.

## Linked entities

- **Genes:** TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901]
- **Chemicals:** 3-methylglutaconic acid (PubChem CID 1551553)
- **Diseases:** Barth syndrome (MONDO:0010543), dilated cardiomyopathy (MONDO:0005021), neutropenia (MONDO:0001475)

## Full-text entities

- **Genes:** TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, DNASE1L1 (deoxyribonuclease 1 like 1) [NCBI Gene 1774] {aka DNAS1L1, DNASEX, DNL1L, G4.8, XIB}
- **Diseases:** muscle fatigue (MESH:D005221), cardiomegaly (MESH:D006332), cardiomyopathy (MESH:D009202), cardiac disease (MESH:D006331), congestive heart failure (MESH:D006333), coryza (MESH:D003139), neutropenia (MESH:D009503), atrium (MESH:D064752), mitochondrial abnormalities (MESH:D028361), growth abnormalities (MESH:D006130), fibrosis (MESH:D005355), 3-methylglutaconic aciduria (MESH:C579867), Mendelian disorder (MESH:D025861), cough (MESH:D003371), X-linked disorder (MESH:D040181), endocardial fibroelastosis (MESH:D004695), DCM (MESH:D002311), lactic acidosis (MESH:D000140), Barth syndrome (MESH:D056889)
- **Chemicals:** Glycogen (MESH:D006003), agarose (MESH:D012685), MLCL (MESH:C067188), TRIzol (MESH:C411644), Ponceau S Red (MESH:C032756), phospholipid (MESH:D010743), CL (MESH:D002308), DMSO (MESH:D004121), tween (MESH:D011136), 1X 3-morpholinopropane-1-sulfonic acid (-), methionine (MESH:D008715), Bis-Tris (MESH:C026272), nitrogen (MESH:D009584), EDTA (MESH:D004492), 3-methylglutaconic acid (MESH:C022034)
- **Species:** Homo sapiens (human, species) [taxon 9606], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932]
- **Mutations:** c.-72_109+51del, c.-111_5del, g.154411733-154411848del
- **Cell lines:** 000116.5 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_SK72)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950784/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12950784/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950784/full.md

---
Source: https://tomesphere.com/paper/PMC12950784